机构：[1]Departments of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[2] Departments of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[3] Lian Jiang People's Hospital, Lian Jiang, China[4] Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China[5] Guangzhou First People Hospital, Guangzhou, China[6] Departments of Breast Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China中山大学附属第一医院[7] Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China., Nanning, China[8] Departments of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China[9] Departments of Breast Oncology, Genenral Hospital of PLA Guangzhou Military Area, Guangzhou, China[10] Departments of Breast Oncology, Shenzhen Second People's Hospital, Shenzhen, China深圳市第二人民医院深圳市康宁医院深圳医学信息中心[11] Departments of Breast Oncology, Haikou People’s Hospital, Haikou, China[12] Departments of Breast Oncology, Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou, China广东省中医院[13] Departments of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, China[14] Departments of Medical Oncology, Foshan First People's Hospital, Foshan, China, Foshan, China[15] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China[16] Department of Medical Oncology, Sun Yat-sen University Cancer Center[17] State Key Laboratory of Oncology in South China[18] Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[19] Sun Yat-Sen university Cancer Center, Guangzhou, China[20] Sun Yat-sen University Affiliated Cancer Hospital, Guangzhou, China
第一作者机构：[1]Departments of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[2] Departments of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[3] Lian Jiang People's Hospital, Lian Jiang, China[4] Departments of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China[5] Guangzhou First People Hospital, Guangzhou, China[6] Departments of Breast Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China[7] Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China., Nanning, China[8] Departments of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China[9] Departments of Breast Oncology, Genenral Hospital of PLA Guangzhou Military Area, Guangzhou, China[10] Departments of Breast Oncology, Shenzhen Second People's Hospital, Shenzhen, China[11] Departments of Breast Oncology, Haikou People’s Hospital, Haikou, China[12] Departments of Breast Oncology, Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou, China[13] Departments of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, China[14] Departments of Medical Oncology, Foshan First People's Hospital, Foshan, China, Foshan, China[15] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China[16] Department of Medical Oncology, Sun Yat-sen University Cancer Center[17] State Key Laboratory of Oncology in South China[18] Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[19] Sun Yat-Sen university Cancer Center, Guangzhou, China[20] Sun Yat-sen University Affiliated Cancer Hospital, Guangzhou, China
推荐引用方式(GB/T 7714)：
Wang Xi,Wang Shu-Sen,Huang Heng,et al.Phase Ill trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(15):doi:10.1200/JCO.2020.38.15_suppl.507.
APA：
Wang, Xi,Wang, Shu-Sen,Huang, Heng,Cai, Li,Peng, Rou-Jun...&Yuan, Zhongyu.(2020).Phase Ill trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001)..JOURNAL OF CLINICAL ONCOLOGY,38,(15)
MLA：
Wang, Xi,et al."Phase Ill trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).".JOURNAL OF CLINICAL ONCOLOGY 38..15(2020)
医学